Haselmeier has a worldwide reputation for its patient-friendly, high-tech innovations. The new Pergoveris® Pen, developed for its customer Merck, has once again confirmed the company's high standard of development.
The leading science and technology company Merck announced recently "that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has given a positive assessment of the new Pergoveris® pen in an official statement".
Haselmeier sees itself as a strategic partner to pharmaceutical and biotechnological companies for the development and production of innovative application aids which are intended to bring relief to patients' lives and improve their quality of life across the board.
The Pergoveris® pen for Merck represents a further innovative self-injection system from Haselmeier for treating women who want to conceive, to add to its other pre-filled, ready-to-use pen injection aids. The advantages of the new pen which is available in three dosage strengths of 300 IU, 450 IU and 900 IU are obvious: The ease of operation has been significantly improved, and it now offers patients the highest level of safety in administering the drug — correctly mixed with the right dosage. Added to this is the fact that doctors can now respond even better to the particular needs of their patients as the dosage can be adjusted in steps of 12.5 IU during treatment.
Dr. Sascha Pohl, Deputy Development Manager at Haselmeier: "This is an important step for Merck and Haselmeier which we can both be proud of. We are enabling our customer Merck to maintain its Family of Pens™ series on the market with a worthy successor. This generation of pens has again succeeded in exceeding patients' needs. It's a nice feeling to be able to make your own contribution through your commitment to project planning."